Kingworld Medicines Group (HKSE:01110) LT-Debt-to-Total-Asset : 0.12 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Kingworld Medicines Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Kingworld Medicines Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.12.

Kingworld Medicines Group's long-term debt to total assets ratio increased from Dec. 2022 (0.01) to Dec. 2023 (0.12). It may suggest that Kingworld Medicines Group is progressively becoming more dependent on debt to grow their business.

Kingworld Medicines Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Kingworld Medicines Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kingworld Medicines Group LT-Debt-to-Total-Asset Chart

Kingworld Medicines Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.12

Kingworld Medicines Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.01	0.01	0.12

Kingworld Medicines Group LT-Debt-to-Total-Asset Calculation

Kingworld Medicines Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	171.064	/	1463.093
	=	0.12

Kingworld Medicines Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	171.064	/	1463.093
	=	0.12

Kingworld Medicines Group (HKSE:01110) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Kingworld Medicines Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Kingworld Medicines Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kingworld Medicines Group (HKSE:01110) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kingworld Medicines Group Ltd (HKSE:01110) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

198 Daxin Road, 8th-9th Floor, Block A, Majialong Chuangxin Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518016

Website

https://www.kingworld.com.cn

Kingworld Medicines Group Ltd is engaged in Distribution sales of pharmaceutical and healthcare products such as branded imported pharmaceutical and healthcare products primarily in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices primarily carried out in the PRC. It derives the majority of its revenue from Distribution sales of pharmaceutical and healthcare products segment.

Executives

Chan Lok San	2101 Beneficial owner
Zhao Li Sheng	2101 Beneficial owner
Sinopharm Capital Limited	2201 Interest of corporation controlled by you
Sinopharm Healthcare Fund L.p.	2101 Beneficial owner
Sun Hill Capital Investments Limited	2201 Interest of corporation controlled by you
Wu Aimin	2201 Interest of corporation controlled by you
Sun Hill Capital Investments Limited	2201 Interest of corporation controlled by you
Wu Aimin	2201 Interest of corporation controlled by you

Kingworld Medicines Group (HKSE:01110) Headlines

No Headlines